Kabra Drugs Intrinsic Value
KABRADG Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹8.53 | ₹6.82 - ₹10.24 | -70.0% | EPS: ₹0.20, Sector P/E: 22x |
| Book Value Method | asset | ₹20.83 | ₹18.75 - ₹22.91 | -26.7% | Book Value/Share: ₹10.42, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹23.33 | ₹21.00 - ₹25.66 | -17.9% | Revenue/Share: ₹11.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹11.37 | ₹10.23 - ₹12.51 | -60.0% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹8.53 | ₹7.68 - ₹9.38 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹8.53 | ₹7.68 - ₹9.38 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹8.53 | ₹7.68 - ₹9.38 | -70.0% | EPS: ₹0.20, BVPS: ₹10.42 |
Want to compare with current market value? Check KABRADG share price latest .
Valuation Comparison Chart
KABRADG Intrinsic Value Analysis
What is the intrinsic value of KABRADG?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Kabra Drugs (KABRADG) is ₹8.53 (median value). With the current market price of ₹28.43, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹8.53 to ₹23.33, indicating ₹8.53 - ₹23.33.
Is KABRADG undervalued or overvalued?
Based on our multi-method analysis, Kabra Drugs (KABRADG) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.00 | Industry Standard: <0.5 | Below 1.0 | Indicates financial leverage level |
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.12x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Kabra Drugs
Additional stock information and data for KABRADG
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |